Synergistic enhancement of chemotherapy for bladder cancer by photothermal dual-sensitive nanosystem with gold nanoparticles and PNIPAM  

作　　者：Xiangqian Cao Chenkai Yang Xiaodong Zhu Mengxin Zhao Yilin Yan Zhengnan Huang Jinming Cai Jingming Zhuang Shengzhou Li Wei Li Bing Shen 

机构地区：[1]Department of Urology,Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200080,China [2]Department of Nanomedicine&Shanghai Key Lab of Cell Engineering,Naval Medical University,Shanghai 200433,China

出　　处：《Chinese Chemical Letters》2024年第8期471-474,共4页中国化学快报（英文版）

基　　金：funded by the National Natural Science Foundation of China(Nos.92059112,82072821,31470964);the Shanghai Songjiang Municipal Science and Technology Commission Natural Science Foundation(No.20SJKJGG250);University of Shanghai for Science and Technology(No.10–21–302–405);sponsored by the Program of Shanghai Academic Research Leader(No.22XD1404700)

摘　　要：Bladder cancer is a common malignant tumor of the urinary system with the potential to be treated by nano drug delivery system.The current work describes the synthesis and characterization of a novel nanomaterial to construct a nano-carrier based on 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphatecholine(POPC)loaded doxorubicin(DOX)and embedded with gold nanoparticles and poly(N-isopropyl acry-lamide)(PNIPAM)(GNPS@PNIPAM-POPC-DOX,GPPD).The dual-sensitive nanosystem gives simultaneous photothermal treatment and chemotherapy for bladder cancer.In vitro and in vivo properties were as-sessed using bladder cancer cell lines and mice and GPPD system distribution,tumor inhibition,and biocompatibility are reported.The system had favorable stability,low biological toxicity,controlled re-lease efficiency,photothermal synergistic action,efficient photothermal transition,and favorable tumor suppressive effects.As a result,GPPD is a potential therapeutic approach for bladder cancer.

关 键 词：DOXORUBICIN Gold nanoparticles Thermosensitive polymer Photothermal therapy Bladder cancer 

分 类 号：R737.14[医药卫生—肿瘤] TB383.1[医药卫生—临床医学]